This study evaluated the efficacy of praziquantel (PZQ), artesunate (AS) alone and combined PZQ-AS targeting Schistosoma mansoni immature-21days old schistosomula. PZQ & AS were administrated in a single oral dose (500 & 400mg/kg, respectively) alone or in combination 21 days post-infection (PI). Infected mice were sacrificed 56 days PI, parasitological, histological parameters and serum anti-SEA antibodies were evaluated. PZQ-monotherapy didn’t significantly affect total worm burden (TWB), female worm fecundity (FWF) or tissue egg load. AS-monotherapy significantly reduced TWB by 69.93%, FWF by 61.56% & tissue ova (hepatic by 91.54%& intestinal by 91.04%).Also, PZQ-AS combined treatment (21 days PI) significantly enhanced the developed worm eradication by 89.69%, FWF by 93.98% with maximal reduction of hepatic and intestinal egg load by 97.08 & 96.96%, respectively. Livers showed diminished granulomata when PZQ-AS was given 3 weeks PI with maximal drop in serum levels of anti-SEA specific IgM, total IgG, IgG1 & IgG2 antibodies.
MADBOULY, N. A., & EL AMIR, A. M. (2021). ARTESUNATE COMBINED WITH PRAZIQUANTEL THERAPY MODULATE THE ANTIBODY RESPONSE IN MURINE SCHISTOSOMIASIS MANSONI. Journal of the Egyptian Society of Parasitology, 51(3), 443-450. doi: 10.21608/jesp.2021.210419
MLA
NEVEEN A. MADBOULY; AZZA M. EL AMIR. "ARTESUNATE COMBINED WITH PRAZIQUANTEL THERAPY MODULATE THE ANTIBODY RESPONSE IN MURINE SCHISTOSOMIASIS MANSONI", Journal of the Egyptian Society of Parasitology, 51, 3, 2021, 443-450. doi: 10.21608/jesp.2021.210419
HARVARD
MADBOULY, N. A., EL AMIR, A. M. (2021). 'ARTESUNATE COMBINED WITH PRAZIQUANTEL THERAPY MODULATE THE ANTIBODY RESPONSE IN MURINE SCHISTOSOMIASIS MANSONI', Journal of the Egyptian Society of Parasitology, 51(3), pp. 443-450. doi: 10.21608/jesp.2021.210419
VANCOUVER
MADBOULY, N. A., EL AMIR, A. M. ARTESUNATE COMBINED WITH PRAZIQUANTEL THERAPY MODULATE THE ANTIBODY RESPONSE IN MURINE SCHISTOSOMIASIS MANSONI. Journal of the Egyptian Society of Parasitology, 2021; 51(3): 443-450. doi: 10.21608/jesp.2021.210419